31E9 (ATCC® HB-11052)

Organism: human (B cell); human (leukemia)  /  Cell Type: hybridoma: T lymphocyte  /  Disease: Allergen

Permits and Restrictions

View Permits

Organism human (B cell); human (leukemia)
Cell Type hybridoma: T lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease Allergen
Applications
The cells produce antigen specific GIF.
Derivation
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
Clinical Data
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
Genes Expressed
Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF)
Cellular Products
Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF)
Comments
Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells).
The cells produce antigen specific GIF.
Cryj-1 is a 40000 dalton glycoprotein that constitutes the major allergen in Japanese cedar pollen.
Complete Growth Medium The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell culture grade water. To make the complete growth medium, add the following components to the base medium:
  • fetal bovine serum to a final concentration of 10%
  • 1.5 g/L sodium bicarbonate for use with 5% CO2 in air atmosphere.
  • Subculturing
    Medium Renewal: Every 2 to 3 days
    Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
    Name of Depositor La Jolla Institute for Allergy and Immunology
    U.S. Patent Number
    Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
    References

    Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996

    Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998

    Notice: Necessary PermitsPermits

    These permits may be required for shipping this product:

    • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
    Basic Documentation
    References

    Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996

    Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998